Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial by Koichi Takayama et al.
ORIGINAL ARTICLE
Anamorelin (ONO-7643) in Japanese patients with non-small cell
lung cancer and cachexia: results of a randomized phase 2 trial
Koichi Takayama1 & Nobuyuki Katakami2 & Takuma Yokoyama3 & Shinji Atagi4 &
Kozo Yoshimori5 & Hiroshi Kagamu6 & Hiroshi Saito7 & Yuichi Takiguchi8 &
Keisuke Aoe9 & Akira Koyama10 & Naoyuki Komura10 & Kenji Eguchi11
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Purpose Cancer cachexia is characterized by decreased body
weight (mainly lean body mass [LBM]) and negatively im-
pacts quality of life (QOL) and prognosis. Anamorelin (ONO-
7643) is a novel selective ghrelin receptor agonist under de-
velopment for treating cancer cachexia.
Methods In this double-blind, exploratory phase 2 trial, we
examined the efficacy and safety of anamorelin in Japanese
patients (n = 181) with non-small cell lung cancer (NSCLC)
and cancer cachexia (≥5 % weight loss within the previous
6 months). The participants were randomized into three
groups and were administered 50 or 100 mg anamorelin, or
placebo, orally every day for 12 weeks. The co-primary end-
points were the changes from baseline over 12 weeks in LBM
and handgrip strength (HGS). Secondary endpoints included
body weight, QOL, Karnofsky Performance Scale (KPS), and
serum biomarkers.
Results The change in LBM over 12 weeks was 0.55 and
1.15 kg in the placebo and 100-mg anamorelin groups, respec-
tively, but the efficacy of anamorelin in HGSwas not detected.
The changes in body weight were −0.93, 0.54, and 1.77 kg in
the placebo, 50-mg anamorelin, and 100-mg anamorelin
groups, respectively. Anamorelin (100 mg) significantly im-
proved KPS and QOL-ACD compared with placebo.
Administration of anamorelin for 12weekswas well tolerated.
Conclusions This phase 2 study showed that 100 mg
anamorelin has promising results in improving lean body
mass, performance status, and especially, QOL in patients
with cancer cachexia.
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Introduction
Cachexia is frequently associated with a variety of clinically
relevant features, including anorexia, inflammation, insulin
resistance, and muscle protein breakdown, and these features
are driven by muscle wasting. However, pre-cachexia may
occur in the absence of weight loss, and obesity or prior
weight loss may mask its symptoms in some patients [1].
Cachexia is a frequent disorder in cancer patients and is cited
as the cause of death in about 20 % of cancer patients [2–6].
Furthermore, cancer cachexia may also be accompanied by
increased chemotherapy-related toxicity [1], as well as poor
prognosis and poor quality of life (QOL) [7].
There are several treatment options available for the man-
agement of patients with cachexia. For example, megestrol
acetate is available for first-line therapy in AIDS-related ca-
chexia in some countries (but not Japan). In a clinical trial of
cancer cachexia, megestrol acetate significantly improved ap-
petite and weight gain compared with placebo [8]. However,
megestrol acetate tends to increase fat mass rather thanmuscle
mass [9], and in a clinical trial [8], it did not improve QOL and
was associated with a higher incidence of adverse events com-
pared with placebo.
Ghrelin, a neuropeptide secreted by ghrelinergic cells in the
gastrointestinal tract, is a regulator of hunger signals that also
prepares the body for food intake. In addition, ghrelin acts as a
growth hormone (GH) secretagogue [10, 11]. In humans,
ghrelin has antagonistic effects on leptin signaling and signif-
icantly increases food intake [12–14]. Therefore, ghrelin mi-
metics have been postulated as possible treatments for cachex-
ia by increasing GH secretion and promoting food intake and
weight gain.
Structure–function relationship studies have revealed that
the C-terminal part of ghrelin plays an important role in its
receptor binding and biological activity [15]. Accordingly, the
structure of this region was used as the basis for the develop-
ment of anamorelin (ONO-7643), an orally administered low-
molecular-weight ghrelin-like agonist with the chemical struc-
ture 3-{(2R)-3-{(3R)-3-benzyl-3-[(trimethylhydrazino) car-
bonyl] piperidin-1-yl}-2-[(2-methylalanyl) amino]-3-
oxopropyl}-1H-indole [16, 17]. Preclinical studies have dem-
onstrated that anamorelin is a potent ghrelin receptor agonist
that significantly increases food intake and body weight in rats
[18], and does not promote tumor growth, which is a potential
concern for molecules that increase GH and insulin-like
growth factor-1 (IGF-1) levels [19]. Subsequent phase 1 and
phase 2 studies of anamorelin have been completed in healthy
volunteers and patients with cancer cachexia in the USA
[20–22]. These studies confirmed that anamorelin significant-
ly increased body weight and food intake compared with pla-
cebo. More recently, two completed phase 3 studies of
anamorelin showed that anamorelin for 12 weeks was well
tolerated and significantly improved lean body mass (LBM),
body weight, and anorexia-cachexia symptoms/concerns in
advanced non-small cell lung cancer (NSCLC) patients with
cachexia; these multinational trials were conducted in North
America, Europe, and Australia [23]. However, no studies
have examined the effects of anamorelin in Japanese patients
with cancer cachexia. Therefore, the aim of this study was to
examine the efficacy and safety of anamorelin in Japanese
patients with cancer cachexia as part of the clinical develop-
ment of anamorelin for the treatment of cachexia.
This trial included patients with NSCLC because these pa-
tients typically showweight loss and are less likely to drop out
owing to disease progression than are patients with other can-
cer types. Additionally, these patients were expected to toler-
ate food intake and administration of anamorelin.
Furthermore, to minimize any potential confounding effects




This multicenter, randomized, double-blind, placebo-
controlled study comprised a 2-week observation/run-in peri-
od, a 12-week treatment period, and a 4-week follow-up pe-
riod, and it was conducted at 32 sites in Japan. Visits during
the treatment period were scheduled at weeks 0 (baseline/ran-
domization), 4, 8, and 12. The study was conducted in com-
pliance with the Declaration of Helsinki, the study protocol,
Paragraph 3 of Article 14 and Article 80-(2) of the
Pharmaceutical Affairs Law of Japan, and Good Clinical
Practice Guidelines (Ministry of Health and Welfare
Ordinance No. 28). The study was approved by ethics com-
mittees at all participating institutions. Clinical trial registra-
tion: JapicCTI-111415 (Japan Pharmaceutical Information
Center Clinical Trials Information).
Patients
Males or females with inoperable stage III or IV NSCLC, or
relapsed NSCLC indicated for chemotherapy, were eligible if
they satisfied the following inclusion criteria: aged ≥20 years
at the time of informed consent; had involuntary weight loss
of ≥5 % observed over the preceding 6 months; at least three
of anorexia, fatigue, malaise, decreased general muscle
strength, arm muscle circumference (AMC) (in cm) <10th
percentile and at least one of C-reactive protein (CRP)
>5.0 mg/L, hemoglobin <12 g/dL, or albumin <3.2 g/dL; an
Eastern Cooperative Group Performance Status of 1 or 2; and
an estimated life expectancy of ≥4 months. Anorexia, fatigue,
malaise, and decreasedmuscle strength were to be of grade ≥ 1
according to the Japanese Version of the NCI Common
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Terminology Criteria for Adverse Events (CTCAE) Version
4.0. AMCwas calculated using the formula: AMC (cm) = arm
circumference (AC) (cm) − 3.14 × triceps skin fold thickness
(TSF) (mm)/10.
Patients with known brain metastases or uncontrolled dia-
betes were excluded from the study. All patients provided
written informed consent, and after registration, eligible pa-
tients were randomized by a central allocation center with
stratification by study site and weight loss over the preceding
6 months (5–15 % and >15 %). Randomization was per-
formed using a randomization table and the sealed envelope
method.
Interventions and concomitant therapy
Patients were randomized to receive 50 or 100 mg of
anamorelin or placebo once daily during the treatment period.
To maintain blinding, all patients took two tablets (two 50-mg
tablets, one 50-mg tablet plus placebo tablet, or two placebo
tablets). The active and placebo tablets were identical in ap-
pearance and packaging. The doses of anamorelin and the
duration of administration were chosen based on previous
studies [24].
High-emetic-risk chemotherapy (categorized according to
the “antiemetics proper use guidelines Version 1” by Japan
Society of Clinical Oncology), radiation therapy (except pal-
liative radiotherapy for bone metastasis or radiotherapy for
brain metastases), systemic corticosteroids, GH preparations,
medroxyprogesterone, megestrol acetate, Chinese herbal
medicines (Anchusan, orento, saireito, juzentaihoto,
shosaikoto, seishoekkito, ninjin’yoeito, heiisan, hochuekkito,
rikkunshito, junshousan), antiarrhythmic drugs, antitumor
anthracyclines, CYP3A4 inhibitors, CYP3A4 inducers,
grapefruit-containing products, and other investigational treat-
ments were prohibited during the study.
Efficacy assessments
The primary endpoints were the mean changes in LBM, as
measured by dual energy X-ray absorptiometry (DEXA) and
grip strength of the non-dominant hand from baseline through
to Week 12. Other endpoints included the changes in body
composition-related variables, as determined by DEXA and
bioimpedance, grip strength, body weight, Japanese Version
of the M.D. Anderson Symptom Inventory (MDASI-J), QOL
Questionnaire for Cancer Patients Treated with Anticancer
Drugs (QOL-ACD), ECOG PS, Karnofsky Performance
Scale, and serum biomarkers. All efficacy variables were de-
termined at baseline (start of observation) and weeks 4, 8, and
12. The efficacy variables were also measured following treat-
ment discontinuation.
DEXAwas performed using Hologic (Bedford, MA, USA)
or GE Lunar (Wauwatosa, WI, USA) systems capable of
whole-body scans; scans were performed ≥48 h after any
use of contrast medium to avoid interference. DEXAwas used
to measure LBM, body fat, bone mineral content, and total
weight using standard procedures. Bioimpedance was also
used to record LBM, body fat, bone mineral content, body
cell mass, and body weight using established methods.
Bioimpedance was performed using an InBody720 (InBody
Japan Inc., Tokyo, Japan) instrument provided by the sponsor.
Grip strength was measured three times for each hand using a
grip dynamometer (Tracker Freedom®Wireless Grip; JTECH
Medical Midvale, UT, USA). The maximum value of the three
measurements was recorded for each hand, and the dominant/
non-dominant hand was noted.
The MDASI-J is a self-rated scale covering 13 symptom
items and 6 interference items, which shows good validity and
practicality for assessing cancer-related symptoms within the
last 24 h by 11 scales [25]. The Japanese version has been
validated and showed good consistency with the English ver-
sion. The QOL-ACD (Supplementary Materials) is a self-
rated scale evaluating patients’ status within the past few days
by five scales, comprised of four domains (functional, physi-
cal, mental, and psychosocial) and a global face scale was
developed as a generic questionnaire for evaluating the QOL
of Japanese patients undergoing chemotherapy. All four do-
mains displayed moderate–strong associations with clinically
relevant variables, such as performance status and weight loss
in Japanese patients with NSCLC [26]. Performance status
was examined in terms of the ECOG PS and Karnofsky
Performance Scale. Blood samples were collected after a
≥12-h fast to measure the concentrations of IGF-1, IGF bind-
ing protein-3 (IGFBP-3), interleukin (IL)-6, tumor necrosis
factor (TNF)α, IL-1β, prealbumin, acylghrelin, and des-
acylghrelin. Laboratory tests were performed at a central lab-
oratory (SRL Medisearch Ltd.).
Safety
Safety variables included vital signs, 12-lead electrocar-
diography, tumor status (assessed using the Response
Evaluation Criteria in Solid Tumors [RECIST] guide-
lines), patient outcomes/survival, clinical laboratory
tests, and adverse events. Overall survival was deter-
mined using the life-table method for each treatment
group. Adverse events were assessed using the
Japanese version of the National Cancer Institute
Common Terminology Criteria for Adverse Events ver.
4.0 and were categorized by system organ class/
preferred term.
Adverse events were also assessed in terms of their sever-
ity, seriousness, causal relationship to the study drug, out-
come, clinical course, and whether the study drug was
discontinued.
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Statistical analyses
In accordance with the pre-specified study protocol and statis-
tical analysis plan, all efficacy variables were first analyzed in
the per-protocol set (PPS) and then confirmed using the full
analysis set (FAS). The FAS included all eligible subjects who
underwent at least one efficacy evaluation after starting the
study drug. The PPS comprised all eligible subjects who did
not receive any of the prohibited treatments and whose LBM
(DEXA) and grip strength were measured during the observa-
tion period and at least once after starting the study drug.
Safety analyses were performed using the safety analysis set,
which was defined as all subjects who were administered the
study drug at least once.
The sample size was calculated based on the result of a
phase 2 study in which the mean ± standard deviation (SD)
difference in LBM (DEXA) between 50 mg anamorelin and
placebo was 2.09 ± 3.06 kg. At a significance level of 5 % and
power of 80 %, at least 35 subjects were needed per treatment
group. Considering that about 35 % of patients were likely to
be excluded from the PPS, we planned to enroll 54 patients per
group. All efficacy data are presented for the PPS, as specified
in the statistical analysis plan, and the results were confirmed
using the FAS. Baseline variables were analyzed descriptively
to determine the mean ± SD or n (%) of patients. Efficacy
variables were analyzed using analysis of covariance with
treatment group, time-point, and preceding weight loss (5–
15 % and >15 %) as fixed factors and the baseline value as a
covariate. The least squares (LS) mean change from baseline
to the indicated time-point was calculated for each group. The
LS mean difference in the anamorelin groups relative to the
placebo groups was also calculated with 95 % confidence
intervals (CIs). An interaction of treatment group × time-point
was also included for secondary efficacy endpoints (changes
in body composition measured by DEXA or bioimpedance,
grip strength, body weight, MDASI-J, QOL-ACD, Karnofsky
Performance Scale, and serum biomarkers). Safety variables
were analyzed descriptively and are shown as n (%) patients.
Overall survival was determined using the Kaplan–Meier
method and was compared among the three groups using
log-rank tests. As this was an exploratory study, no adjustment
was made for multiplicity of statistical testing, and missing
data were not imputed.
Protocol modifications
Some modifications were made to the statistical analysis plan,
but all changes were implemented before unblinding. In brief,
the study duration and patient enrollment were extended be-
cause it took longer than expected to enroll the target number
of patients. We also reassessed the target sample size, as we
originally planned to enroll 44 patients per group after antic-
ipating that 20 % of treated patients would be excluded from
the PPS; this was increased to 35%. Additionally, because the
US Food and Drug Administration issued new guidance on
CYP3A4 inhibitors after starting this trial, the use of these
drugs was added to the exclusion criteria and list of prohibited
drugs. These criteria were retrospectively applied to all pa-
tients in the PPS and FAS.
Results
Patients
Between March 2011 and September 2012, 181 subjects were
enrolled and randomized to placebo, 50-mg anamorelin, or
100-mg anamorelin groups (Supplementary Fig. 1). Two pa-
tients did not receive treatment. The PPS comprised 115 pa-
tients, with 42, 42, and 31 in the placebo, 50-mg anamorelin,
and 100-mg anamorelin groups, respectively (Supplementary
Fig. 1). There were 12, 8, and 6 deaths in the placebo, 50-mg
anamorelin, and 100-mg anamorelin groups, respectively,
while 6, 14, and 13 patients, respectively, discontinued owing
to adverse events. All three groups were comparable in terms
of their baseline characteristics (Table 1).
Lean body mass and non-dominant handgrip strength
Compliance with the study drugs was high because
≥96 % of patients took ≥80 % of their allocated drugs.
As shown in Fig. 1a, the increase in LBM from base-
line was significantly greater in the 100-mg anamorelin
group at weeks 8 and 12 than in the placebo group,
although the LS mean change from baseline to week
12 was of borderline significance. The results in the FAS
were consistent with those in the PPS, with LS mean ± SE
changes of 0.19 ± 0.31 kg, and 1.07 ± 0.31 kg in the placebo
and 100-mg anamorelin groups, respectively. The difference
compared with placebo was 0.89 kg (95%CI 0.29, 1.48 kg) in
the 100-mg anamorelin group (P = 0.0037). Although 50 mg
anamorelin also increased LBM, the difference comparedwith
placebo was not significant.
There were no changes in non-dominant handgrip strength
in any group (Fig. 1b).
QOL-ACD
Significant improvements were identified in the 100-mg
anamorelin group compared with the placebo group in the
QOL-ACD total score and the scores for items 1–6 “daily
activity,” 7–11 “physical condition,” 8 “Did you have a good
appetite?,” and 9 “Did you enjoy your meals?” (Fig. 2a–e).
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Body weight
Consistent with its mechanism of action and the increase in
LBM, Fig. 3a shows that administration of anamorelin 100
and 50 mg resulted in significant body weight gain compared
with placebo. These increases in bodyweight were apparent at
week 4 and were sustained for the duration of the study.
Karnofsky performance scale
Administration of 100 mg anamorelin significantly in-
creased patients’ Karnofsky Performance Scale from
baseline to weeks 4 and 12 relative to placebo, but no
changes were detected in the 50-mg anamorelin group
(Fig. 3b).









Sex Male 39 (65.0) 50 (76.9) 35 (63.6)
Female 21 (35.0) 15 (23.1) 20 (36.4)
Age (years) Mean ± SD 66.0 ± 9.4 64.8 ± 8.7 65.7 ± 8.8
Weight (kg) Mean ± SD 52.31 ± 10.29 51.10 ± 8.53 52.30 ± 11.57
BMI (kg/m2) Mean ± SD 19.80 ± 2.86 19.33 ± 2.57 20.23 ± 3.21
Weight loss (%) 5 to <10 36 (62.1) 38 (58.5) 38 (69.1)
10 to 15 20 (34.5) 16 (24.6) 14 (25.5)
> 15 2 (3.4) 11 (16.9) 3 (5.5)
Body composition (DEXA) (kg) LBM 38.65 ± 6.80 38.77 ± 6.20 38.80 ± 7.58
Body fat 11.30 ± 5.26 10.12 ± 4.44 11.70 ± 5.06
BMC 1.92 ± 0.48 1.90 ± 0.47 1.91 ± 0.55
Grip strength (kg) Dominant hand 24.91 ± 9.05 27.32 ± 8.29 25.32 ± 9.28
Non-dominant
hand
23.73 ± 9.31 25.79 ± 7.70 23.31 ± 9.24
Sum of both
hands
48.64 ± 18.09 53.12 ± 15.59 48.63 ± 18.13
QOL MDASI-J 50.9 ± 33.4 49.0 ± 36.9 55.6 ± 37.2
QOL-ACD 73.4 ± 13.9 71.3 ± 14.9 70.6 ± 13.9
ECOG PS 1 46 (79.3) 47 (72.3) 45 (81.8)
2 12 (20.7) 18 (27.7) 10 (18.2)
Histological type of NSCLC Adenocarcinoma 47 (78.3) 44 (69.8) 43 (79.6)
Squamous cell 10 (16.7) 15 (23.8) 7 (13.0)
Other 3 (5.0) 4 (6.4) 4 (7.4)
Missing – 2 1
Disease stage IIIA 5 (8.3) 8 (12.3) 8 (14.5)
IIIB 3 (5.0) 9 (13.8) 4 (7.3)
IV 45 (75.0) 38 (58.5) 38 (69.1)
Recurrence 7 (11.7) 9 (13.8) 5 (9.1)
Other – 1 (1.5) –
Time from diagnosis to starting the
study drug (days)
Mean ± SD 549.0 ± 422.3 627.1 ± 572.6 466.6 ± 436.7
History of chemotherapy (number of
lines)
0 – 1 (1.5) –
1 9 (15.0) 15 (23.1) 17 (30.9)
2 19 (31.7) 12 (18.5) 14 (25.5)
≥3 32 (53.3) 37 (56.9) 24 (43.6)
Values are expressed as the n (%) of patients or mean ± SD
SD standard deviation, BMI body mass index, DEXA dual energy X-ray absorptiometry, LBM lean body mass,
BMC bone mineral content, QOL quality of life, MDASI-J M.D. Anderson Symptom Inventory, ACD
Questionnaire for Cancer Patients Treated with Anticancer Drugs (Kurihara Group Questionnaire), ECOG PS
Eastern Cooperative Group Performance Status, NSCLC non-small cell lung cancer, CRP C-reactive protein, Hb
hemoglobin, Alb albumin
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Other secondary endpoints
The effects of anamorelin on the other secondary endpoints,
including serum biomarkers/laboratory variables, measures of
body composition (as measured by DEXA and bioimpedance),
grip strength, and MDASI-J, are shown in Supplementary
Tables 1 and 2. The serum biomarkers IGF-1, IGFBP-3, and
prealbumin were significantly increased in patients taking
100 mg anamorelin compared with placebo. Even in patients
taking 50 mg anamorelin, these parameters showed increases;
however, the magnitude of the changes was smaller than those
observed in the 100-mg anamorelin group. (Fig. 4a–c). There
were no changes in IL-1β, IL-6, TNFα, acylghrelin, or des-
acylghrelin (Supplementary Table 1). In terms of the other sec-
ondary endpoints, 100 mg anamorelin was also associated with
significant increases in body fat measured by DEXA at each
timepoint (Supplementary Table 2).
Safety
The tumor responses according to RECIST were classified as
complete response, partial response, stable disease, progres-
sive disease, and non-evaluable in 0, 4 (7.0 %), 11 (19.3 %),
24 (42.1 %), and 14 (24.6 %) patients, respectively, in the
placebo group; in 0, 3 (4.6 %), 14 (21.5 %), 27 (41.5 %),
and 15 (23.1 %) patients, respectively, in the 50-mg
anamorelin group; and in 1 (1.8 %), 1 (1.8 %), 20 (36.4 %),
23 (41.8 %), and 9 (16.4 %), patients, respectively, in the 100-
mg anamorelin group. The overall survival rates were not
significantly different among the three groups (hazard ratio
[95 % CI]; placebo vs. 50 mg anamorelin: 0.91 [0.62, 1.33];
placebo vs. 100 mg anamorelin: 0.74 [0.50, 1.10];
Supplementary Fig. 2).
The overall incidences of adverse events, adverse drug re-
actions, severe adverse drug reactions, and deaths are shown
in Table 2. The incidence of adverse events was comparable in
all three groups. However, the incidence of adverse drug re-
actions was significantly greater in both anamorelin groups
compared with the placebo group. The incidence of
Grade ≥ 3 adverse drug reactions was similar in each group
(Table 2). Considering the patient population, most of the
deaths were attributed to malignant neoplasm progression,
and these events were not deemed related to the study drugs.
In either anamorelin-treated group, ≥20 % of patients de-
veloped nausea, vomiting, increased C-reactive protein, in-
creased glycosylated hemoglobin, neutrophil count decreased,
or decreased hemoglobin and white blood cell count. Of these
events, only nausea and increased glycosylated hemoglobin
occurred in ≥5 % patients in the anamorelin groups than in the
placebo group.
Discussion
This study revealed that administration of 100 mg anamorelin
































Placebo 50 mg 100 mg
Change from baseline to 
Week 12 (kg)
n 42 42 30
LSM SE 0.55 0.29 0.85 0.26 1.15 0.31
Diﬀerence vs. placebo (kg) LSM (95% CI) - 0.30 (−0.26, 0.87)
0.60 (0.00,
1.21)





Placebo 50 mg 100 mg
Change from baseline to 
Week 12 (kg)
n 42 42 31
LSM SE 0.45 0.62 0.02 0.55 1.07 0.67 
Diﬀerence vs. placebo







































Placebo (n = 42)
50 mg anamorelin 
(n = 42)
100 mg anamorelin 
(n = 30)
Placebo (n = 42)
50 mg anamorelin 
(n = 42)
100 mg anamorelin 
(n = 31)
Fig. 1 Effects of anamorelin on lean body mass (a) and grip strength (non-dominant hand; b). CI confidence interval, LSM least squares mean, SE
standard error
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LBM, body weight, QOL, and statistically significant in-
creases in the serum biomarkers IGF-1, IGFBP-3, and
prealbumin compared with placebo. By contrast, 50 mg
anamorelin was not associated with marked improvements
in most of these variables compared with placebo. These find-
ings indicate that 100 mg anamorelin is the most effective
dose in Japanese patients with NSCLC. The efficacy of
anamorelin was not confirmed in handgrip strength, IL-1β,
IL-6, TNFα, acylghrelin, or des-acylghrelin.
Several clinical trials of anamorelin have been conducted
[20, 21, 27]. In a phase 1, multiple-dose study, anamorelin was
associated with dose-related increases in body weight over
6 days in healthy volunteers, with the greatest increase ob-
served after once-daily dosing of 50 mg [21]. In a pharmaco-
dynamic study in healthy volunteers, anamorelin (25, 50, and
75 mg) was associated with dose-related increases in body
weight and significant increases in GH, IGF-1, and IGFBP-3

























Placebo (n = 42)
50 mg anamorelin 
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P = 0.0499 P = 0.0482
Placebo (n = 42)
50 mg anamorelin 
(n = 42)














0                    4                      8                 12   Week
a bFig. 3 Effects of anamorelin on
body weight (a) and Karnofsky
performance scale (b)
8. Did you have a good appete? 9. Did you enjoy your meals?






































































Fig. 2 Effects of anamorelin on the QOL-ACD total score (a) and the scores for items 1–6 “daily activity” (b), items 7–11 “physical condition (c), item 8
“Did you have a good appetite?” (d), and item 9 “Did you enjoy your meals?” (e)
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In a pooled analysis of two phase 2 studies in patients with
cancer cachexia, 50 mg anamorelin was associated with a sig-
nificant increase in LBM (LS mean 1.89 kg, 95 % CI 0.84,
2.95 kg) compared with placebo (−0.20, 95 % CI −1.23,
0.83), corresponding to a between-group difference of 2.09 kg
(95 % CI 0.94, 3.25, P = 0.0006) [27]. In two phase 3 studies in
patients with NSCLC and cachexia, 100 mg anamorelin was
associated with significantly improved LBM, body weight,
and anorexia-cachexia symptoms/concerns [23].
In the present study, 50 and 100 mg anamorelin were asso-
ciated with placebo-subtracted increases in body weight of
0.76 and 0.89 kg, respectively. Consistent with earlier phar-
macodynamic studies [22], our study revealed increases in
IGF-1 and IGFBP-3 levels in patients treated with 100 mg
anamorelin that are suggestive of increased muscle protein
synthesis. These changes are consistent with the increases in
LBM. We also observed a significant increase in prealbumin,
a marker of the nutritional state.
Anamorelin (100 mg) was also associated with significant
improvements in QOL-ACD, especially items 8 and 9, which
focus on appetite and meal enjoyment, and also increases in
daily activity, and improvements in physical condition. These
findings indicate that patients treated with 100 mg anamorelin
reported greater appetite during treatment and were more like-
ly to enjoy their meals as compared with placebo-treated pa-
tients. Additionally, the increase in the Karnofsky Performance
Scale suggests there were improvements in the functional status
of this cohort of patients.
The overall survival times and tumor responses according
to RECIST were generally similar in each treatment group,
which indicates that the treatment itself did not modify disease
progression. Furthermore, there were no differences in patient
characteristics (e.g., disease stage and history of chemothera-
py) or existing prognostic factors, among the three groups.
The incidence of adverse drug reactions was signifi-
cantly greater in both anamorelin groups than in the
placebo group, but there were very few serious drug
reactions and the distribution of Grade 3–5 events was
similar in all three groups. Notably, most deaths and
treatment discontinuations were due to disease progres-
sion rather than the study drugs themselves. Although






































Fig. 4 Effects of anamorelin on insulin-like growth factor-1 (a), insulin-like growth factor binding protein-3 (b), and prealbumin (c)
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more patients in the anamorelin groups than in the pla-
cebo group, neither adverse event was considered a sig-
nificant risk. This suggests that anamorelin is tolerable
in Japanese patients with cancer cachexia.
This study has several limitations. Firstly, the efficacy of
anamorelin was not confirmed in handgrip strength.
Secondary, the bioimpedance might have not been suitable
as a method to determine LBM, body fat, etc. for the patients
with cancer cachexia. Thirdly, since this is an exploratory
study, multiple comparisons were not performed; it should
be performed in a larger-sized study to be conducted in the
future.
Conclusions
In conclusion, 100 mg anamorelin once daily had favor-
able effects on LBM in Japanese NSCLC patients suf-
fering from cachexia, suggesting that this dose should
be preferred in this patient population. Treatment with
anamorelin was accompanied by increases in IGF-1 and
IGFBP-3, which are indicative of an increase in protein
synthesis, and an increase in prealbumin, indicative of
improved nutritional status. Furthermore, anamorelin
was associated with favorable improvements in QOL,
appetite, and performance status. Although the incidence
of adverse drug reactions and discontinuations because
of adverse events were greater in the anamorelin groups,
the majority of treatment discontinuations were related
to disease progression rather than anamorelin.
Cancer cachexia requires multimodal treatment such
as nutrition, exercise, and pharmacotherapies. The pro-
file of anamorelin shown in this study indicates a great
potential of the safe and effective drug as an option for
the pharmacotherapies for multimodal treatment of can-
cer cachexia.
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Table 2 Adverse events and
adverse drug reactions Placebo 50 mg anamorelin 100 mg anamorelin
n 58 65 55
Adverse events 58 (100.0) 61 (93.8) 53 (96.4)
Difference (%) vs. placebo (95 % CI) −6.2 (−12.0, −0.3) −3.6 (−8.6, 1.3)
P value 0.0548 0.1428
Serious adverse events 29 (50.0) 26 (40.0) 17 (30.9)
Discontinuations due to adverse events 6 (10.3) 14 (21.5) 13 (23.6)
Adverse drug reactions 12 (20.7) 25 (38.5) 29 (52.7)
Difference (%) vs. placebo (95 % CI) 17.8 (2.0, 33.5) 32.0 (15.2, 48.9)
P value 0.0319 0.0004
Serious adverse drug reactions 4 (6.9) 3 (4.6) 0 (0.0)
Discontinuations due to adverse drug reactions 2 (3.4) 4 (6.2) 5 (9.1)
Deaths 12 (20.7) 8 (12.3) 6 (10.9)
Adverse events by grade
Grade 3 17 (29.3) 23 (35.4) 15 (27.3)
Grade 4 13 (22.4) 9 (13.8) 11 (20.0)
Grade 5 13 (22.4) 11 (16.9) 7 (12.7)
Adverse events in ≥20 % of patients
in either anamorelin group
White blood cell count decreased 18 (31.0) 20 (30.8) 14 (25.5)
Neutrophil count decreased 15 (25.9) 19 (29.2) 13 (23.6)
CRP increased 19 (32.8) 16 (24.6) 10 (18.2)
Hemoglobin decreased 15 (25.9) 14 (21.5) 11 (20.0)
Nausea 10 (17.2) 9 (13.8) 17 (30.9)
Vomiting 10 (17.2) 14 (21.5) 6 (10.9)
Glycosylated hemoglobin increased 0 (0) 4 (6.2) 11 (20.0)
Values are expressed as the n (%) of patients
CI confidence interval
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